LIVIVO - Search results -

Search results

Result 1 - 10 of total 101

Search options

Book: DAS ISOENZYMSYSTEM DER AMYLASE1 (AMY-E.C.: 3.2.1.1), BESTIMMUNGSTECHNIK MITTELS ISOELEKTROFOKUSSIERUNG AUF POLYACRYLAMIDGELEN UND BESCHREIBUNG EINES NEUEN ALLELS, AMY5,1

Tischberger, Hubert

1982

Title variant	ISOENZYMSYSTEM DER AMYLASE AMY-E. C. : BESTIMMUNGSTECHNIK MITTELS ISOELEKTROFOKUSSIERUNG AUF POLYACRYLAMIDGELEN UND BESCHREIBUNG EINES NEUEN ALLELS, AMY
Size	54 S. : ILL., GRAPH. DARST.
Document type	Book
Note	FRANKFURT (MAIN), UNIV., DISS., 1982
HBZ-ID	HT002625659
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
82 D 1454	order for loan	Magazin

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Book ; Thesis: Das Isoenzymsystem der Amylase1 <AMY-E.C.: 3.2.1.1>

Tischberger, Hubert

1982

Author's details	Hubert Tischberger
Language	Undetermined
Size	54 S, Ill., graph. Darst
Document type	Book ; Thesis
Thesis / German Habilitation thesis	@Frankfurt (Main), Univ., Diss. : 1982
Database	Former special subject collection: coastal and deep sea fishing

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: The use and misuse of the SCOFF screening measure over two decades: a systematic literature review.

Coop, Amy / Clark, Amelia / Morgan, John / Reid, Fiona / Lacey, J Hubert

Eating and weight disorders : EWD

2024 Volume 29, Issue 1, Page(s) 29

Abstract: Purpose: The SCOFF questionnaire was designed as a simple, memorable screening tool to raise suspicion that a person might have an eating disorder. It is over 20 years since the creation of the SCOFF, during which time it has been widely used. ... ...

Abstract	Purpose: The SCOFF questionnaire was designed as a simple, memorable screening tool to raise suspicion that a person might have an eating disorder. It is over 20 years since the creation of the SCOFF, during which time it has been widely used. Considering this, we wish to review the use of the SCOFF in peer-reviewed scientific journals, and to assess whether it is being used appropriately in the manner in which it was originally devised and tested. Methods: The Preferred Reporting Items for a Systematic Review and Meta-analysis (PRISMA) guidelines were followed, and all search strategies and methods were determined before the onset of the study. PubMed and Wiley Online Library were searched using the terms SCOFF and eating. Two reviewers were involved in the reviewing process. Criteria for appropriate use of the SCOFF were formalised with the tool's original authors. Results: 180 articles were included in the final review. 48 articles had used the SCOFF appropriately, 117 articles inappropriately and 15 articles had been mixed in the appropriateness of their use. Conclusion: This systematic review highlights the inappropriate use of the SCOFF in diverse languages and settings. When used correctly the SCOFF has made a significant contribution to the understanding of eating disorders and its simplicity has been applauded and led to widespread use. However in over two-thirds of studies, the use of the SCOFF was inappropriate and the paper highlights how and in what way it was misused, Guidelines for the appropriate use of the SCOFF are stated. Future validation and avenues of research are suggested. Level of evidence: Level I.
MeSH term(s)	Humans ; Feeding and Eating Disorders/diagnosis ; Surveys and Questionnaires ; Mass Screening/methods
Language	English
Publishing date	2024-04-23
Publishing country	Germany
Document type	Journal Article ; Systematic Review ; Review
ZDB-ID	2038625-4
ISSN	1590-1262 ; 1124-4909
ISSN (online)	1590-1262
ISSN	1124-4909
DOI	10.1007/s40519-024-01656-6
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5566: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Inflammatory myofibroblastic tumor of the bladder in an adolescent: Case report.

Guan, Linda / Khan, Azeem / Zhou, Amy / Swana, Hubert S

Urology case reports

2023 Volume 52, Page(s) 102598

Abstract: Inflammatory myofibroblastic tumors of the bladder (IMTB) are rare neoplasms that can occur in children. These tumors have uncertain malignant potential and can present similarly to bladder sarcomas. It is important to differentiate between IMTB and ... ...

Abstract	Inflammatory myofibroblastic tumors of the bladder (IMTB) are rare neoplasms that can occur in children. These tumors have uncertain malignant potential and can present similarly to bladder sarcomas. It is important to differentiate between IMTB and bladder sarcomas using a careful immunohistochemical approach. We report a case of IMTB in a 12-year-old girl who presented with presyncope and gross hematuria. IMTB was diagnosed through immunohistochemical analysis, and clinical improvement was observed after resection of the tumor.
Language	English
Publishing date	2023-10-20
Publishing country	United States
Document type	Case Reports
ZDB-ID	2745459-9
ISSN	2214-4420
ISSN	2214-4420
DOI	10.1016/j.eucr.2023.102598
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Haemoglobin changes and disease activity in Japanese patients with rheumatoid arthritis treated with sarilumab.

Tanaka, Yoshiya / Takahashi, Toshiya / Van Hoogstraten, Hubert / Praestgaard, Amy / Kato, Naoto / Kameda, Hideto

Clinical and experimental rheumatology

2022 Volume 41, Issue 5, Page(s) 1129–1139

Abstract: Objectives: Anaemia is a frequent extra-articular manifestation in rheumatoid arthritis (RA); haemoglobin level changes are associated with changes in disease activity. This post-hoc analysis assessed potential relationships between haemoglobin and ... ...

Abstract	Objectives: Anaemia is a frequent extra-articular manifestation in rheumatoid arthritis (RA); haemoglobin level changes are associated with changes in disease activity. This post-hoc analysis assessed potential relationships between haemoglobin and disease activity in Japanese patients with RA, enrolled in the KAKEHASI study (NCT02293902). Methods: In this study, adult patients with moderate-to-severe active RA, who had an inadequate response to methotrexate, were randomised to subcutaneous sarilumab 150 mg every 2 weeks (q2w) or 200 mg q2w or placebo for 24 weeks. Post-hoc analyses were conducted on changes in haemoglobin and proportion of anaemic patients, using a mixed-effects model for repeated measures assuming an unstructured covariance. Relationships between haemoglobin and efficacy measures were explored. Results: At baseline, nearly half of patients had anaemia, defined by World Health Organization criteria (haemoglobin <12 g/dL, female; or <13 g/dL, male). At Week 24, the least squares mean change in haemoglobin levels was greater in sarilumab groups than for placebo (150 mg: 1.23 g/dL, 200 mg: 1.19 g/dL, placebo: 0.17 g/dL; p=0.0002 for both doses vs. placebo). By Week 24, the proportion of patients with anaemia was 17.8%, 22.9%, and 30.1% for sarilumab 150 mg, 200 mg, and placebo, respectively. Conclusions: In Japanese patients with RA, both doses of sarilumab were associated with greater improvement in haemoglobin levels and reduction in proportion of patients with anaemia, compared with placebo. Sarilumab may be a suitable treatment for patients with RA and anaemia.
MeSH term(s)	Adult ; Female ; Humans ; Male ; Anemia/drug therapy ; Anemia/etiology ; Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/diagnosis ; Arthritis, Rheumatoid/drug therapy ; Double-Blind Method ; East Asian People ; Hemoglobins ; Methotrexate ; Treatment Outcome
Chemical Substances	Antirheumatic Agents ; Hemoglobins ; Methotrexate (YL5FZ2Y5U1) ; sarilumab (NU90V55F8I)
Language	English
Publishing date	2022-10-28
Publishing country	Italy
Document type	Randomized Controlled Trial ; Journal Article
ZDB-ID	605886-3
ISSN	1593-098X ; 0392-856X
ISSN (online)	1593-098X
ISSN	0392-856X
DOI	10.55563/clinexprheumatol/jq9u8f
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2002: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A Lower Frequency of Spliceosome Mutations Distinguishes Clonal Cytopenias of Undetermined Significance From Low-Risk Myelodysplastic Syndromes, Despite Inherent Similarities in Genomic, Laboratory, and Clinical Features.

Ferrone, Christina K / McNaughton, Amy J M / Rashedi, Iran / Ring, Brooke / Buckstein, Rena / Tsui, Hubert / Rauh, Michael J

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

2023 Volume 36, Issue 3, Page(s) 100068

Abstract: Clonal cytopenias of undetermined significance (CCUS) are associated with an increased risk of developing a myelodysplastic syndrome (MDS); however, the mechanism and factors associated with evolution remain unclear. We propose that next-generation ... ...

Abstract	Clonal cytopenias of undetermined significance (CCUS) are associated with an increased risk of developing a myelodysplastic syndrome (MDS); however, the mechanism and factors associated with evolution remain unclear. We propose that next-generation sequencing (NGS) of cytopenic cases with equivocal morphologic dysplasia will improve patient clinical care and that serial sequencing of such equivocal cases could identify the factors that predict evolution to MDS. We performed targeted NGS of samples from 193 individuals with confirmed or suspected MDS or MDS/myeloproliferative neoplasm, including sequential investigation for 28 individuals at the time of diagnosis and during follow-up. NGS facilitated the diagnosis of all suspicious cases as myeloid neoplasm (21%), CCUS (34%), or idiopathic cytopenias of undetermined significance (45%) when no variants were detected. We found that there was no significant difference in most measured clinical features or clonal phenotypes, such as cell counts, number of variants, variant allele frequencies, and overall survival, between CCUS and International Prognostic Scoring System-Revised-defined low-risk MDS. However, there was a significant difference in the types of variants between CCUS and low-risk MDS, with a significantly lower number of splicing factor mutations in CCUS cases (P < .001). Moreover, we observed an increased probability of evolution to MDS of individuals with CCUS compared with that in those with idiopathic cytopenias of undetermined significance over the first 5 years (P = .045). Our analyses revealed no conclusive pattern associating clonal expansion or the number of variants with the evolution of CCUS to MDS, perhaps further supporting the similarity of these diseases and the clinical importance of recognizing and formally defining CCUS as a category of precursor myeloid disease state in the next revision of the World Health Organization guidelines.
MeSH term(s)	Humans ; Spliceosomes ; Mutation ; Myelodysplastic Syndromes/diagnosis ; Myelodysplastic Syndromes/genetics ; Myelodysplastic Syndromes/complications ; Genomics ; Neoplasms
Language	English
Publishing date	2023-01-10
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	645073-8
ISSN	1530-0285 ; 0893-3952
ISSN (online)	1530-0285
ISSN	0893-3952
DOI	10.1016/j.modpat.2022.100068
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2450: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Improvement or Worsening of Disease Activity After Switch to Sarilumab in Patients With Rheumatoid Arthritis With a Partial Response to Adalimumab.

Curtis, Jeffrey R / Aletaha, Daniel / Burmester, Gerd / Ford, Kerri / van Hoogstraten, Hubert / Praestgaard, Amy / Bykerk, Vivian P

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases

2023 Volume 29, Issue 4, Page(s) 196–201

Abstract: Objective: The aim of this study was to assess the effect of switching from adalimumab to sarilumab monotherapy in partial responders with rheumatoid arthritis from the MONARCH randomized trial and its open-label extension (OLE).: Methods: Partial ... ...

Abstract	Objective: The aim of this study was to assess the effect of switching from adalimumab to sarilumab monotherapy in partial responders with rheumatoid arthritis from the MONARCH randomized trial and its open-label extension (OLE). Methods: Partial response was defined as improvement in Clinical Disease Activity Index (CDAI) of 12 or 6 units (baseline score: >22 or >10 and ≤22, respectively). Proportions of adalimumab partial responders with meaningful worsening or improvement at OLE weeks 12 and 24 were evaluated using 2 CDAI thresholds (≥6 and ≥12 points), 28-joint Disease Activity Score using erythrocyte sedimentation rate (≥0.6 and ≥1.2 points), Health Assessment Questionnaire Disability Index (≥0.22 and ≥0.30 points), Simple Disease Activity Index (≥7 and ≥13 points), physician and patient global assessments (≥10 and ≥20), and 28-joint swollen and tender joint counts (≥1 and ≥2 joints). Outcomes were analyzed using mixed-effect models with repeated measures for observed cases. The p values were produced using Wilcoxon tests. Results: Of 369 enrolled patients, 320 (87%) entered the OLE and 155 switched from adalimumab to sarilumab; 59% (91/155) were partial responders. At week 24, 4%-17% and 2%-12% of partial responders experienced a worsening using the lower and higher thresholds, respectively, whereas 47%-78% and 27%-66% experienced improvement. Conclusions: Partial responders to adalimumab who switched to sarilumab had a low likelihood of experiencing meaningful worsening, with most patients showing meaningful improvement or no change in disease activity. This may help alleviate patients' fears of worsening when considering switching to a treatment with a different mechanism of action.
MeSH term(s)	Humans ; Adalimumab/adverse effects ; Antirheumatic Agents/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; Arthritis, Rheumatoid/diagnosis ; Arthritis, Rheumatoid/drug therapy ; Treatment Outcome ; Double-Blind Method
Chemical Substances	Adalimumab (FYS6T7F842) ; sarilumab (NU90V55F8I) ; Antirheumatic Agents ; Antibodies, Monoclonal, Humanized
Language	English
Publishing date	2023-03-02
Publishing country	United States
Document type	Journal Article
ZDB-ID	1283266-2
ISSN	1536-7355 ; 1076-1608
ISSN (online)	1536-7355
ISSN	1076-1608
DOI	10.1097/RHU.0000000000001946
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4815: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Correction: Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry.

Curtis, Jeffrey R / Yun, Huifeng / Chen, Lang / Ford, Stephanie S / van Hoogstraten, Hubert / Fiore, Stefano / Ford, Kerri / Praestgaard, Amy / Rehberg, Markus / Choy, Ernest

Rheumatology and therapy

2023 Volume 11, Issue 1, Page(s) 217

Language	English
Publishing date	2023-10-31
Publishing country	England
Document type	Published Erratum
ZDB-ID	2783278-8
ISSN	2198-6584 ; 2198-6576
ISSN (online)	2198-6584
ISSN	2198-6576
DOI	10.1007/s40744-023-00607-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Understanding China's political will for sustainability and conservation gains

Hubert Cheung / Yutong Phoenix Feng / Amy Hinsley / Tien Ming Lee / Hugh P. Possingham / Stephen N. Smith / Laura Thomas‐Walters / Yifu Wang / Duan Biggs

People and Nature, Vol 5, Iss 1, Pp 57-

2023 Volume 68

Abstract: Abstract Political will is a critical determinant of the success or failure of environmental policies and interventions. Harnessing the political will necessary to implement environmental solutions can be challenging because environmental priorities may ... ...

Abstract	Abstract Political will is a critical determinant of the success or failure of environmental policies and interventions. Harnessing the political will necessary to implement environmental solutions can be challenging because environmental priorities may compete with other societal interests in policymaking. Environmental solutions are more politically feasible if fundamentally aligned with the core interests of key policymakers. Understanding the political agendas of decision‐makers enables conservationists to identify where political will already exists, and allows environmental objectives to piggyback on the motivation to deliver results. In this paper, we explore the core interests of the Chinese leadership to uncover opportunities to leverage Beijing's political will for sustainability and conservation gains. China's growing influence on ecosystems and natural resource use both within and beyond its borders makes an analysis of its leadership's political will valuable and timely. Read the free Plain Language Summary for this article on the Journal blog.
Keywords	Beijing ; Chinese leadership ; development strategy ; geopolitics ; People's Republic of China ; political agenda ; Human ecology. Anthropogeography ; GF1-900 ; Ecology ; QH540-549.5
Subject code	950
Language	English
Publishing date	2023-02-01T00:00:00Z
Publisher	Wiley
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Disproportionate articular pain is a frequent phenomenon in rheumatoid arthritis and responds to treatment with sarilumab.

Choy, Ernest / Bykerk, Vivian / Lee, Yvonne C / van Hoogstraten, Hubert / Ford, Kerri / Praestgaard, Amy / Perrot, Serge / Pope, Janet / Sebba, Anthony

Rheumatology (Oxford, England)

2022 Volume 62, Issue 7, Page(s) 2386–2393

Abstract: Objectives: In some patients with RA, joint pain is more severe than expected based on the amount of joint swelling [referred to as disproportionate articular pain (DP)]. We assessed DP prevalence and the effects of sarilumab, an IL-6 inhibitor, on DP.!# ...

Abstract	Objectives: In some patients with RA, joint pain is more severe than expected based on the amount of joint swelling [referred to as disproportionate articular pain (DP)]. We assessed DP prevalence and the effects of sarilumab, an IL-6 inhibitor, on DP. Methods: Data from RA patients treated with placebo or 200 mg sarilumab in the phase 3 randomized controlled trials (RCTs) MOBILITY and TARGET, adalimumab 40 mg or sarilumab 200 mg in the phase 3 RCT MONARCH and sarilumab 200 mg in open-label extensions (OLEs) were used. DP was defined as an excess tender 28-joint count (TJC28) over swollen 28-joint count (SJC28) of ≥7 (TJC28 - SJC28 ≥ 7). Treatment response and disease activity were determined for patients with and without DP. Results: Of 1531 sarilumab 200 mg patients from RCTs, 353 (23%) had baseline DP. On average, patients with DP had higher 28-joint DAS using CRP (DAS28-CRP) and pain scores than patients without DP, whereas CRP levels were similar. After 12 and 24 weeks, patients with baseline DP treated with sarilumab were more likely to be DP-free than those treated with placebo or adalimumab. In RCTs, more sarilumab-treated patients achieved low disease activity vs comparators, regardless of baseline DP status. In OLEs, patients were more likely to lose rather than gain DP status. Conclusion: About one-quarter of patients with RA experienced DP, which responded well to sarilumab. These data support the concept that other mechanisms (potentially mediated via IL-6) in addition to inflammation may contribute to DP in RA. Trial registrations: NCT01061736, NCT02332590, NCT01709578, NCT01146652.
MeSH term(s)	Humans ; Adalimumab/therapeutic use ; Antirheumatic Agents/adverse effects ; Methotrexate/therapeutic use ; Interleukin-6 ; Treatment Outcome ; Arthritis, Rheumatoid/complications ; Arthritis, Rheumatoid/drug therapy ; Arthritis, Rheumatoid/chemically induced ; Arthralgia/etiology ; Arthralgia/chemically induced
Chemical Substances	Adalimumab (FYS6T7F842) ; sarilumab (NU90V55F8I) ; Antirheumatic Agents ; Methotrexate (YL5FZ2Y5U1) ; Interleukin-6
Language	English
Publishing date	2022-11-22
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1464822-2
ISSN	1462-0332 ; 1462-0324
ISSN (online)	1462-0332
ISSN	1462-0324
DOI	10.1093/rheumatology/keac659
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 240: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 497: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito